217 related articles for article (PubMed ID: 19470736)
1. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
3. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Fan H; Lu X; Wang X; Liu Y; Guo B; Zhang Y; Zhang W; Nie J; Feng K; Chen M; Zhang Y; Wang Y; Shi F; Fu X; Zhu H; Han W
J Immunol Res; 2014; 2014():371087. PubMed ID: 24963497
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
5. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
Aparicio A; North B; Barske L; Wang X; Bollati V; Weisenberger D; Yoo C; Tannir N; Horne E; Groshen S; Jones P; Yang A; Issa JP
Epigenetics; 2009 Apr; 4(3):176-84. PubMed ID: 19421002
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L; Flynn J; Plass C; Marcucci G; Chan KK; Grever MR; Byrd JC
Br J Haematol; 2010 Jul; 150(2):189-95. PubMed ID: 20456354
[TBL] [Abstract][Full Text] [Related]
7. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
9. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
Liu Z; Liu S; Xie Z; Blum W; Perrotti D; Paschka P; Klisovic R; Byrd J; Chan KK; Marcucci G
Nucleic Acids Res; 2007; 35(5):e31. PubMed ID: 17264127
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
12. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
Jacobberger JW; Woost PG
Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
[TBL] [Abstract][Full Text] [Related]
13. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Vijayaraghavalu S; Labhasetwar V
Cancer Lett; 2013 Apr; 331(1):122-9. PubMed ID: 23305699
[TBL] [Abstract][Full Text] [Related]
16. An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma.
Mei Q; Chen M; Lu X; Li X; Duan F; Wang M; Luo G; Han W
Oncotarget; 2015 Jun; 6(18):16698-711. PubMed ID: 25895027
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Appleton K; Mackay HJ; Judson I; Plumb JA; McCormick C; Strathdee G; Lee C; Barrett S; Reade S; Jadayel D; Tang A; Bellenger K; Mackay L; Setanoians A; Schätzlein A; Twelves C; Kaye SB; Brown R
J Clin Oncol; 2007 Oct; 25(29):4603-9. PubMed ID: 17925555
[TBL] [Abstract][Full Text] [Related]
18. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.
Tsai HC; Li H; Van Neste L; Cai Y; Robert C; Rassool FV; Shin JJ; Harbom KM; Beaty R; Pappou E; Harris J; Yen RW; Ahuja N; Brock MV; Stearns V; Feller-Kopman D; Yarmus LB; Lin YC; Welm AL; Issa JP; Minn I; Matsui W; Jang YY; Sharkis SJ; Baylin SB; Zahnow CA
Cancer Cell; 2012 Mar; 21(3):430-46. PubMed ID: 22439938
[TBL] [Abstract][Full Text] [Related]
19. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.
Frazzi R; Cusenza VY; Pistoni M; Canovi L; Cascione L; Bertoni F; Merli F
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751409
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
